Back

Modifiable risk factors and 5-year and lifetime risks of cardiovascular disease among 0.5 million hypertensive patients in primary care

30 August 2026 (08:15 - 09:00)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy in hypertension Lifestyle Modification ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Jiangshui Wang

State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular D, Beijing (China)

5 More presentations in this session

Presentation thumbnail
Baseline characteristics and antihypertensive patterns in Finnish patients with hypertension and kidney disease
Professor T. Niiranen (Turku, FI)
Abstract Slides
Presentation thumbnail
Artificial intelligence-assisted personalised dose titration for hypertension: safety and feasibility results of the CURATE.AI pilot randomised controlled trial
Doctor X. Tadeo (Singapore, SG)
Abstract Slides
Presentation thumbnail
Renal function and hyperkalemia with first-line eplerenone in obese patients with hypertension: randomized safety data from the HEBRO trial
Doctor P. Iliakis (Athens, GR)
Abstract Slides
Presentation thumbnail
Predicting individual blood pressure response to additional antihypertensive treatment: a prototype decision support tool for healthcare professionals in the community
Associate Professor A. Gupta (London, GB)
Abstract Slides
Presentation thumbnail
Digital AI lifestyle support improves blood pressure control on top of standard dual antihypertensive therapy
Mr B. Rozibaev (Tashkent, UZ)
Abstract Slides

Access the full session

Session thumbnail
Pharmacotherapy in hypertension

The Event

Event poster

ESC Congress 2026

30 August 2026 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Distribution of cardiovascular disease risk in adults aged 40 to 79 years with diagnosed hypertension but not on medications: findings from nationwide cross-sectional studies
25 April 2024
thumbnail
Congress Presentation
Management of modifiable risk factors and comorbidities in atrial fibrillation: suggestions for improvement from a patient perspective
17 April 2023
thumbnail
Congress Presentation
Impact of risk factors globally
26 August 2023
thumbnail
Congress Presentation
Predicted lifetime therapy benefit guided treatment effectively reduces residual cardiovascular risk in patients with symptomatic atherosclerotic disease
29 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources